Trial Profile

Phase Ib/IIa trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TPIV 100 (Primary)
Indications Carcinoma; Ductal carcinoma; Early breast cancer
Focus Therapeutic Use

Most Recent Events

17 Oct 2018 According to a Marker Therapeutics Inc, the TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc.
05 Apr 2018 According to a TapImmune media release, this study is fully funded by a grant from the U.S. DoD.
15 Nov 2017 According to a TapImmune media release, this trial is expected to begin in 1H 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com